Filing Flows › Health Care › Precigen (PGEN)
Precigen (PGEN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Precigen (PGEN) Q3 2026 earnings results →
Q3 2026 Revenue up 2438% year over year to $74.1M · 48¢ of every $1 of revenue kept as net profit · operating margin 52.1%
Precigen made $74.1M in Q3 2026 (25× Y/Y): Product revenues, net $73.0M, Service revenues $1.2M. Operating margin 52.1%, net earnings $35.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $74.1M in Q3 2026, up 2438% year over year and up 35% from the previous quarter. Product revenues, net was the largest line at 98% of revenue. Product revenues, net added $72.8M year over year (up 44936%), 102% of the total change.
Operating profit was $38.6M, a 52.1% margin (up 1232.2 points year over year). Total costs fell 5% while revenue rose 2438%. The fastest-growing cost line was Other operating costs (+529%). Net earnings were $35.8M. The effective tax rate was 0.6%.
Operating cash flow was $11.9M, 33% of net earnings. Non-cash charges added back $1.1M of depreciation and amortization and $3.8M of share-based compensation. Working capital and other items used $28.8M. Capital expenditures of $435K left free cash flow of $11.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $74.1M | 25× | 52.1% | $35.8M | $11.9M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $55.0M | 64× | 41.2% | $20.1M | −$17.8M |
| Q1 2026 | 10-Q | May 13, 2026 | $23.3M | 17× | -25.8% | −$7.9M | −$43.8M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $856K | — | n/m | −$26.6M | −$19.0M |
| Q1 2025 | 10-Q | May 14, 2025 | $1.3M | — | n/m | −$54.2M | −$16.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Precigen
We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies to improve outcomes for a disease or patient population.
In its own words, from its 10-K, filed Mar 25, 2026.
Precigen against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 25× against the peers' median +10%. Operating margin: 52.1% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PGEN Precigen | Q3 2026 | $74.1M | 25× | 52.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Precigen 10-Q on SEC EDGAR · CIK 1356090 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns PGEN and who is buying
More on PGEN
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q2 2025 results · Q1 2025 results